HC Wainwright Has Negative Forecast for NAMS Q2 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for NewAmsterdam Pharma in a research note issued on Thursday, May 7th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.34). HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s Q3 2026 earnings at ($0.58) EPS, Q4 2026 earnings at ($0.25) EPS and FY2026 earnings at ($1.60) EPS.

Several other research firms have also recently weighed in on NAMS. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. Guggenheim boosted their price objective on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Finally, Needham & Company LLC boosted their price objective on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Trading Up 2.2%

NASDAQ:NAMS opened at $39.59 on Tuesday. The firm has a market capitalization of $4.55 billion, a PE ratio of -22.12 and a beta of 0.02. NewAmsterdam Pharma has a 1 year low of $16.78 and a 1 year high of $42.21. The firm’s fifty day simple moving average is $31.95 and its 200 day simple moving average is $34.27.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The company had revenue of $3.04 million for the quarter.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC increased its stake in NewAmsterdam Pharma by 4,425.0% during the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the period. Wells Fargo & Company MN boosted its holdings in NewAmsterdam Pharma by 50.0% during the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV acquired a new stake in NewAmsterdam Pharma during the first quarter valued at approximately $37,000. Navalign LLC acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $46,000. Finally, Wolverine Asset Management LLC acquired a new stake in NewAmsterdam Pharma during the third quarter valued at approximately $69,000. 89.89% of the stock is currently owned by institutional investors.

Insider Activity at NewAmsterdam Pharma

In related news, CEO Michael H. Davidson sold 443,707 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares in the company, valued at $5,790,288. The trade was a 71.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10. Following the transaction, the insider owned 69,302 shares in the company, valued at $2,099,850.60. This represents a 60.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,168,286 shares of company stock worth $38,211,967 over the last three months. Company insiders own 12.74% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.